CONDUCT OF INSPECTIONS OF PHARMACEUTICAL MANUFACTURERS SOP no. GMP-034/03
|
|
- Everett Lester
- 7 years ago
- Views:
Transcription
1 1 of 6 SOP no. GMP-034/03 Jerusalem CONDUCT OF INSPECTIONS OF PHARMACEUTICAL MANUFACTURERS SOP no. GMP-034/03 Name Position Date Signature Dr. Mimi Kaplan Director, Institute for Standardization & Control of Michael Carmi GMP Inspector Dr. Rami Kariv Head of GMP Inspectorate Sara Covrigaro Director, Quality Assurance UNAUTHORIZED COPY
2 2 of 6 SOP no. GMP-034/03 Introduction (the Institute) GMP Inspection Unit is responsible for enforcing the rules of good manufacturing practice (GMP) in Israeli Pharmaceutical manufacturing companies of medicinal products and active pharmaceutical ingredients (API). Its key enforcement tool is on site inspections. The aim of the inspections is to evaluate compliance of the quality system and infrastructure with internationally accepted GMP standards (the reference document being the PIC/S GMP manual). These inspections also examine the compliance of the medicinal products manufactured at the site with the terms of their Israeli registration and quality specifications, as well as the strength and purity of the products required to protect the public health of the consumers. Inspections are divided into preliminary inspections required for approval of a new production line or manufacturing plant, the periodic inspections of licensed plants, and ad hoc Inspections to investigate the suspicion of a major infringement of GMP standards (such as in the case of a product recall, a complaint, or report regarding a major unexpected side effect). The spectrum of manufacturers regulated by the Inspection Unit covers manufacturers of medicinal products, manufacturers of biologicals, medical gas plants and API manufacturers. Inspected plants also divide between those who manufacture for export and are consequently inspected by overseas health authorities and those who manufacture only for the local market and are therefore regulated only by Israel's Ministry of Health. The Inspection Unit is also responsible for inspections of plants which manufacture only for export (if there are such) and for overseas plants of Israeli manufacturers manufacturing products registered exclusively in Israel. 1. Scope 1.1 This SOP sets out a uniform procedure for carrying out inspections in the range of plants falling under Inspection Unit oversight. 1.2 The SOP shall be followed by all Institute inspectors and specialists who carry out GMP inspections. 2. Applicable Documents 2.1 Compilation of Community Procedures on Inspections and Exchange of Information, EMEA/INS/GMP/03/REV SOP for Preparing for a GMP Inspection, GMP SOP for Writing a GMP Inspection Report, GMP SOP for Follow-Up of Corrective actions taken by Manufacturing Plants, GMP SOP for Information Confidentiality, GMP- 031.
3 3 of 6 SOP no. GMP-034/ SOP for Sampling during a GMP Inspection, GMP Definitions 3.1 PIC/S, Pharmaceutical Inspection Corporation Scheme the international professional association of GMP inspectors. 4. Responsibilities 4.1 It is the responsibility of the National GMP Inspector to appoint the members of an inspection team and to ensure that they follow this SOP during inspections. 4.2 It is the responsibility of GMP Inspectors and specialists carrying out an inspection to follow this SOP. 5. Methods 5.1 The Head of the GMP Inspectorate shall appoint the members of each inspection team One inspector shall be appointed to head the team (should the team number more than one inspector) Institute specialists will join the team as necessary, for example For biologicals a biological products specialist; A microbiologist from the microbiology laboratory; A laboratory specialist from the Institute analytical laboratory. 5.2 One of the team inspectors will arrange the inspection date with the manufacturer and carry out the preparatory steps set out in GMP-049, the SOP for Preparing for a GMP Inspection. 5.3 Conduct of Inspectors during a Plant Inspection The inspectors represent a government authority. They must dress accordingly and behave with courtesy The inspectors will follow local patterns of conduct and eating. In plants which provide lunch for their staff, inspectors shall eat together with plant staff In all other cases inspectors shall pay for their meals; In inspections of remote plants in Israel, where the inspection lasts several days and inspectors stay in a nearby hotel, the inspected manufacturer shall not pay for the inspectors' hospitality. 5.4 Inspectors shall act according to Institute procedures for the confidential handling of information. All information discovered by or passed to the inspectors is confidential and shall not be disclosed to any outside person or body. Inspectors shall neither carry with
4 4 of 6 SOP no. GMP-034/03 them written or printed materials relating to other plants, nor disclose any information relating to another company The inspectors task is not only to expose deficiencies. They must answer any professional queries put to them, while as far as a possible abstain from offering advice. 5.5 Inspections shall start with an opening session, at which plant staff set out the structure of the company and its key officials and the inspectors set out the inspection program At this opening session The inspectors shall identify themselves and describe their jobs; The inspectors shall state which documents they need to study once they have completed their preliminary tour of the site. 5.6 There will be a preliminary tour of the site to allow the inspectors to get a general orientation of the site. It can take several forms, either following the flow of materials from storage to final product or following the flow of staff around the plant or any other form that suits the inspectors This preliminary tour should be no more than a quick overview: in general no detailed inspection should be done at this stage. 5.7 Over the course of the inspection the inspectors shall review all procedures, production and laboratory records, validations and any other record or documentation relating to production and control of the production process. 5.8 The inspection shall also include detailed tours of all production facilities, laboratories, stores, technical systems and the plant s record and documentation centre The following specific issues shall be investigated, inter alia: The suitability of the facility for its purpose, including the orderliness of its layout and cleanliness; The production equipment its calibration and cleanliness, preventive maintenance, daily maintenance records Whether production records are fully maintained and in real time Critical systems: air-conditioning, water, clean compressed air, sewage and drainage, any other relevant systems. 5.9 Inspectors shall talk to the staffers who actually carry out the work and not make do with general answers from the quality assurance manager or production manager Samples may be taken during the inspection as the inspectors see fit. In taking samples inspectors shall follow SOP GMP-032. Details of the samples shall be entered on form GMP-032A and the samples taken for examination to the Institute laboratories.
5 5 of 6 SOP no. GMP-034/ Issues that the inspectors believe will figure as deficient in the final inspection report should be talked over with plant staff before the inspectors final meeting with them, in order to give plant representatives the chance to clarify matters incorrectly understood On overseas inspections, where plant procedures and records are written in a language the inspectors do not know, it is the responsibility of the manufacturer to provide the inspectors a written or oral translation into English or Hebrew The inspectors shall ask plant representatives to furnish them copies of documents they wish to take away for further examination or as evidence of a deficiency they have found The plant shall mark and sign the photocopied documents according to its usual internal practice The documents shall be collected into a file, which the inspectors shall take with them at the end of the inspection The documents taken away shall be bound together and kept at the Institute at least until the next inspection The inspection shall conclude with a final session between inspectors and plant representatives. Should the inspectors see fit and the manufacturer agree each day s inspection can also be concluded with such a session The final session shall cover (at least) A detailed listing of the findings and deficiencies found by the inspectors during the course of their inspection; Should a major deficiency come to light during the course of the inspection, representing a grave risk to public health, the inspectors shall take immediate steps to eliminate the risk Post-inspection activities The inspectors shall summarize their findings in an Inspection Report, following SOP GMP-037. The Report shall be sent to the manufacturer within 45 working days The inspectors shall maintain regular oversight over improvements introduced by the manufacturer (see SOP for Monitoring Corrective Measures in a Plant after Inspection). 6. Inspection Documentation 6.1 All inspections shall be recorded in notebooks issued to the inspectors by the Institute quality assurance department. 6.2 The notebook pages shall be pre-numbered.
6 6 of 6 SOP no. GMP-034/ Inspectors shall enter on the first page of each notebook their name, the name and address of the plant under inspection and the date of the inspection. 6.4 No page shall be torn out of a notebook. 6.5 Any deletion or correction in a notebook shall be done in a way that leaves the original text readable. 6.6 Do not write in a notebook in pencil. 6.7 Inspectors shall record all their observations in their notebooks, not just the deficiencies found. 6.8 The Inspectors could record their findings on a mobile computer. At the end of the inspection the file will be printed, signed and added to the notebook. 6.9 Inspection notebooks and the final inspection report shall be kept for at least ten years and then sent to the state archives, in accordance with the State Archivist s instructions All documents removed from a plant shall be kept in the GMP Inspection Unit s offices at least until the next inspection and shall be used to prepare for that inspection Documents removed from a plant may be shredded only after the inspectors have been given up-to-date documents at the next inspection At the time of shredding, care must be taken not to shred from the earlier inspection file the records made by the inspectors during their inspection (notebooks and final report).
Title:: Effective GMP AUDITS for APIs and Formulation Pharma Companies By G.Sundar-Director/Consultant PharmQA Compliance solutions
WELCOME Title:: Effective GMP AUDITS for APIs and Formulation Pharma Companies By G.Sundar-Director/Consultant PharmQA Compliance solutions Contents: Introduction GMP Audit GMP Audit plan GMP Auditing
More informationI. PURPOSE This SOP describes policies, procedures, and record keeping requirements for all documents subject to change control.
SOP Number: SOP -001 Page 1 of 5 4/18/2013 Effective I. PURPOSE This SOP describes policies, procedures, and record keeping requirements for all documents subject to change control. II. SCOPE All SOP s
More informationQUALITY SYSTEM REQUIREMENTS FOR PHARMACEUTICAL INSPECTORATES
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 002-3 25 September 2007 RECOMMENDATION ON QUALITY SYSTEM REQUIREMENTS FOR PHARMACEUTICAL INSPECTORATES PIC/S September
More informationThe Quality System for Drugs in Germany
The Quality System for Drugs in Germany Prof. Dr. Harald G. Schweim Head of Department for Drug Regulatory Affairs Institute for Pharmacy, University of Bonn Former President of the German Federal Institute
More informationComparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE
Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Dr. Fulvio CARLOTTI, GNOSIS SpA, Corporate QA Director September 26, 2014 Scope of GMP GMP compliance
More informationAnnex 7 Guidelines on pre-approval inspections
World Health Organization WHO Technical Report Series, No. 902, 2002 Annex 7 Guidelines on pre-approval inspections 1. General 94 2. Glossary 94 3. Objectives 95 4. Priorities 96 5. Preparation for the
More informationGMP Training Course Inspections from an industry perspective. 20-21 October 2009 Fiona Routley MHRA Inspector (UK)
GMP Training Course Inspections from an industry perspective 20-21 October 2009 Fiona Routley MHRA Inspector (UK) Objective To provide an insight into how arranged inspections are prepared and managed.
More informationLibrary Guide: Pharmaceutical GMPs
Library Guide: Pharmaceutical GMPs Table of Contents Overview...3 Courses Listed by Functional Area... 4 Course Descriptions: A Step-by-Step Approach to Process Validation (PHDV79)... 7 A Tour of the FDA
More informationASTRAZENECA GLOBAL POLICY QUALITY AND REGULATORY COMPLIANCE
ASTRAZENECA GLOBAL POLICY QUALITY AND REGULATORY COMPLIANCE THIS POLICY OUTLINES THE TOP LEVEL REQUIREMENTS TO SUPPORT PRODUCT QUALITY IN THE DEVELOPMENT, MANUFACTURE AND DISTRIBUTION OF ACTIVE PHARMACEUTICAL
More informationQualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015
Qualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015 *QP Code of Practice 2008 updated Aug15 Page 1 of 13 Code of Practice for Qualified Persons 1. INTRODUCTION 2.
More informationRecent Updates on European Requirements and what QPs are expected to do
Recent Updates on European Requirements and what QPs are expected to do QP Forum 28/29 November 2013, Lisbon Dr. Bernd Renger Modified: Georg Goestl 1 Written Conformation for API-Import Actual Status
More informationPreparing for the Pre-Approval Inspection What to do Before the FDA Arrives. Barry A. Friedman, Ph.D. Consultant
Preparing for the Pre-Approval Inspection What to do Before the FDA Arrives Barry A. Friedman, Ph.D. Consultant FDA Overview FDA is a consumer protection agency within the Department of Health & Human
More informationPharmaceutical Wholesaler Site Inspection Checklist
Pharmaceutical Wholesaler Site Inspection Checklist Date and time of inspection: Legal business name and plant name: Location (address): Phone number: Fax number: Email address: Web site URL: Contact Person:
More informationPROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013)
January 2013 RESTRICTED PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013) DRAFT FOR COMMENTS Please address any comments on this proposal
More informationDeviation and Out of Specification Handling
Deviation and Out of Specification Handling APV Training Course GMP Requirements June,10th to11th 2004 Istanbul, Turkey Dr. Jürgen Mählitz GMP Inspector Fronhof 10 D-86152 Augsburg Germany Dr. Jürgen Mählitz
More informationExample of a food company quality
Appendix A manual Example of a food company quality Contents Date: 13/03/95 RME-QLMN-OO Page 1 of 3 Section Title ISO 9001 reference 01 In trod uction 02 Purpose 03 Scope 04 Definitions 05 Management responsibility
More informationQuality Agreement. by and between. Supplier Name. Address: and. Client Name: Address:
NOTE TO USERS This Quality Agreement template was developed by the Bulk Pharmaceutical Task Force (BPTF), an affiliate organization of the Society of Chemical Manufacturers and Affiliates (SOCMA), as a
More informationThere is no Silver Bullet to complying with the US FDA GMPs by Alan Schwartz
There is no Silver Bullet to complying with the US FDA GMPs by Alan Schwartz Recently, we participated in a seminar on United States (US) Food and Drug Administration (FDA) regulations to the Hebei Pharmaceutical
More informationWorld Health Organization Prequalification of Medicines
Dr André van Zyl World Health Organization Prequalification of Medicines Manufacturers meeting April 2011 Head of Inspections vanzyla@who.int 1 WHO GMP In this presentation: Background and Introduction
More informationinternet internet website: website: www.clalglobal.co.il. Email: clalglobalservice@clal-ins.co.il Fax: +972-77-6383448 Fax: +972-77-6383448
Dear Customer, Dear Customer, Further Further to your to request your request to exercise to exercise your rights your in rights accordance in accordance with the with Insurance the Insurance Policy Policy
More informationLIBRARY GUIDE. Online Courses. March 2012
LIBRARY GUIDE Online Courses March 2012 i Table of Contents OVERVIEW..................................................................................... 1 COURSE DESCRIPTIONS (LISTED ALPHABETICALLY)...............................................
More informationSession 6: WHO Prequalification Programme. Key Process Steps WHO: Medicines UNFPA: Condoms and IUDs
Session 6: WHO Prequalification Programme Key Process Steps WHO: Medicines UNFPA: Condoms and IUDs Session adapted from the WHO training workshop on prequalification and the WHO technical briefing seminar
More informationJob description. Job title. Process Engineer. Responsible to. Process Engineering Manager. Hours/sessions per week 37.
Job description Job title Directorate Pay band Responsible to Base/location Process Engineer Production SEO Process Engineering Manager Porton Hours/sessions per week 37.5 Job type Permanent INTRODUCTION
More informationAuthor General Management Quality Assurance
Lab Ofichem B.V. Pag.: 1 / 14 Date: 20-01- Version: 02 Status: geldig Contents 1. General... 2 2. Shared Third Party audit program... 3 3. Reassurance absence of Conflict of Interest... 5 4. Contract structure...
More informationFDA 21 CFR Part 11 Electronic records and signatures solutions for the Life Sciences Industry
FDA 21 CFR Part 11 Electronic records and signatures solutions for the Life Sciences Industry The Rule 21 CFR Part 11 Handwritten signature means the scripted name or legal mark of an individual handwritten
More informationDocuments, Records and Change Control
Documents, Records and Change Control Lori S. Lawless Medical Device Specialist Food and Drug Administration Baltimore District Office Lori.Lawless@fda.hhs.gov (410) 779-5442 May 13-14, 2008 Baltimore
More informationAnnex 1 WHO good practices for pharmaceutical quality control laboratories
World Health Organization WHO Technical Report Series, No. 957, 2010 Annex 1 WHO good practices for pharmaceutical quality control laboratories General considerations Glossary Part one. Management and
More informationNew changes to cleanroom & clean air device classifications: ISO 14644 1 & 2
New changes to cleanroom & clean air device classifications: ISO 14644 1 & 2 This white paper describes the changes outlined in the Draft International Standard (DIS) editions of ISO 14644-1 and ISO 14644-2.
More informationGuidance for Industry: Starting Material Supplier Management
Guidance for Industry: Starting Material Supplier Management Version 1.0 Drug Office Department of Health. Contents 1. Introduction... 3 2. Purpose of this document... 3 3. Scope... 3 4. Selecting and
More informationAudit Report in the framework of the APIC Audit Programme
Audit Report in the framework of the APIC Audit Programme Company Location Address Country Subject of Audit Audit Date Auditor (lead) Co-Auditor(s) Participants Signature of Auditor(s) Lead Auditor Co-Auditor
More informationPhysician s Practice Organization D/b/a Doctors Park Family Medicine Patient Information Brochure. To Our Patients
Physician s Practice Organization D/b/a Doctors Park Family Medicine Patient Information Brochure To Our Patients Thank you for choosing Doctors Park Family Medicine as the healthcare provider for you
More informationA Job Seeker s Guide to Discovery
1 A Job Seeker s Guide to Discovery Discovery is a way to find out what you are good at and what you like to do. In your Discovery program, you will learn about different jobs, try different job tasks,
More informationCOLUMBIA RIVER GORGE COMMISSION. Chapter 350 Division 12. Public Records. As Amended Through April 1, 2008.
COLUMBIA RIVER GORGE COMMISSION Chapter 350 Division 12 Public Records As Amended Through April 1, 2008. 350-12-001. Definitions for 350-12-001 to 350-12-008. (1) "Person" includes any natural person,
More informationNew Guidelines on Good Distribution Practice of Medicinal Products for Human Use (2013/C 68/01)
Safeguarding public health New Guidelines on Good Distribution Practice of Medicinal Products for Human Use (2013/C 68/01) Tony Orme, Senior GDP Inspector Inspection, Enforcement and Standards Division
More informationSTATEMENT OF PRIVACY PRACTICES
STATEMENT OF PRIVACY PRACTICES We, at Seattle Smile Works, are dedicated to protect the privacy rights of our patients and the confidential information entrusted to us. The commitment of each employee
More informationCommercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations
Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations Kevin O Donnell PhD Market Compliance Manager, IMB PDA / FDA Conference Pharmaceutical
More informationNSF Dietary Supplement
NSF Dietary Supplement SOP Template Book A guide to achieving and maintaining compliance to 21 CFR 111: Dietary Supplement Good Manufacturing Practices 2 Contents How to Use...4 About NSF Dietary Supplements...5
More informationGOOD DOCUMENTATION AND QUALITY MANAGEMENT PRINCIPLES. Vimal Sachdeva Technical Officer (Inspector), WHO Prequalification of Medicines Programme
GOOD DOCUMENTATION AND QUALITY MANAGEMENT PRINCIPLES Vimal Sachdeva Technical Officer (Inspector), WHO Prequalification of Medicines Programme Contents 1. Why good documentation is essential? 2. What constitutes
More informationGeorgia Department of Transportation. Office of Materials and Research. Standard Operating Procedure (SOP) 19
Laboratory SOP 19 Revised July 1, 2003 Georgia Department of Transportation Office of Materials and Research Standard Operating Procedure (SOP) 19 This Standard Operating Procedure provides a means whereby
More informationIt s all about managing food. Food Recall Plan Template For Food Manufacturers
It s all about managing food. Food Recall Plan Template For Food Manufacturers What to Do In The Event Of a Product Recall Every Food Distributor and Food Manufacturer must track the products they manufacture
More informationTNRCC WATER QUALITY INVESTIGATOR TRAINING PROGRAM
TNRCC WATER QUALITY INVESTIGATOR TRAINING PROGRAM This document describes the policy and guidance for participation in the Water Quality Investigator Training Program in the Field Operations Division (FOD)
More informationTRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP
DISCLAIMER: The EU reserves the right to make subsequent modifications to this text and to complement its proposals at a later stage, by modifying, supplementing or withdrawing all, or any part, at any
More informationWhite paper: The 10 Golden Rules of GMP
White paper: The 10 Golden Rules of GMP The Good Manufacturing Practice regulations that govern pharmaceutical and medical device manufacturing can seem overwhelming. Use these ten golden rules to drive
More informationALASKA. Downloaded January 2011
ALASKA Downloaded January 2011 7 AAC 12.255. SERVICES REQUIRED A nursing facility must provide nursing, pharmaceutical, either physical or occupational therapy, social work services, therapeutic recreational
More informationRiver Valley Therapy & Sports Medicine, Inc. Notice of Privacy Practices
River Valley Therapy & Sports Medicine, Inc. Notice of Privacy Practices This notice describes how medical information about you may be used and disclosed and how you can get access to this information.
More informationHealth Canada s GCP Compliance Program Part 2. GCP Information Sessions November 2010
Your Health and Safety... Our priority Votre santé et votre Securité notre priorité Health Canada s GCP Compliance Program Part 2 GCP Information Sessions November 2010 Inspection Program Main objectives
More informationOMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT
OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT PA/PH/OMCL (08) 69 3R Full document title and reference Document type VALIDATION OF COMPUTERISED SYSTEMS Legislative basis - CORE DOCUMENT
More informationDATA PROTECTION POLICY
DATA PROTECTION POLICY The Hollandse School Limited (hereinafter HSL ) is an educational institution with a history of over 93 years, and is one of the largest Dutch language schools abroad where the International
More informationPRIVACY NOTICE. In certain situations, we may also disclose patient information to another provider or health plan for their health care operations.
1 PRIVACY NOTICE THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND HOW YOU CAN GET ACCESS TO THIS INFORMATION. PLEASE REVIEW IT CAREFULLY. This Privacy Notice is being
More informationUNICEF s Quality Assurance System for procurement of medicines
UNICEF s Quality Assurance System for procurement of medicines QA Specialist Peter Svarrer Jakobsen Joint UNICEF, UNFPA and WHO Meeting with Manufacturers and Suppliers UN City, Copenhagen 23 September
More informationASI 691 Prinicples of HACCP 1
Prerequisite Programs: GMP s, SOP s, SSOP s HACCP Does Not Stand Alone Must be built on existing food safety programs Prerequisite Programs Definition of Prerequisite Programs- Procedures, including Good
More information1 www.imarcresearch.com
Risk Management in Clinical Research: PROCESS DEVELOPMENT & APPLICATION Introduction Recently, two key pieces of guidance were released from Food and Drug Administration (FDA) and European Medicines Agency
More informationOfficer for the Capital Market, Insurance and Savings. Annual Report 2003
Officer for the Capital Market, Insurance and Savings Annual Report 2003 Jerusalem, Kislev 5765, November 2004 Editor: System Coordinator: Hebrew Editor: Design: Typesetting: Preparation and Printing:
More information1. This bulletin, which contains the Charter of the Office of Internal Oversight Services (IOS) of
UNIDO/DGB/(M).92/Rev.3 28 January 2015 Distribution: All staff members at headquarters, established offices and permanent missions 1. This bulletin, which contains the Charter of the Office of Internal
More informationAnnex 10 Procedure for prequalification of pharmaceutical products
World Health Organization WHO Technical Report Series, No. 961, 2011 Annex 10 Procedure for prequalification of pharmaceutical products 1. Introduction 2. Glossary 3. Purpose and principles 4. Steps of
More informationGMP Training Course Quality Control. 20-21 October 2009. Lesley Graham Senior Inspector (UK)
GMP Training Course Quality Control 20-21 October 2009 Lesley Graham Senior Inspector (UK) Quality Control GMP in the QC Laboratory Certificates of Analysis Dealing with out of specification results Parametric
More informationA NUSAGE-PharmEng Pharmaceutical and Biotechnology Training Program
A NUSAGE-PharmEng Pharmaceutical and Biotechnology Training Program Shaping Human Capital for Challenges in the Pharmaceutical Industry CLEANING VALIDATION Instructors Loh Kean Chong Rick Ng Date and Time
More informationPERFORMANCE EVALUATIONS POLICY. Purpose: To provide feedback, coaching and development plans for employees on a regularly scheduled basis.
PERFORMANCE EVALUATIONS POLICY Purpose: To provide feedback, coaching and development plans for employees on a regularly scheduled basis. Policy: Regular, annual performance evaluations are completed for
More informationEudraLex. The Rules Governing Medicinal Products in the European Union Volume 4
Ref. Ares(2015)283695-23/01/2015 PT CHAPTER 5 PRODUCTION EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products quality, safety and efficacy EudraLex
More informationMaster Your Future MA Degree Studies in Israel
Master Your Future MA Degree Studies in Israel המינהל לסטודנטים עולים Israel Student Authority Ministry of Immigrant Absorption GRADUATE IN YOUR PROFESSION ENHANCE YOUR ROOTS BROADEN YOUR EDUCATION IN
More informationAnnex 4 Good Manufacturing Practices for pharmaceutical products: main principles
World Health Organization WHO Technical Report Series, No. 908, 2003 Annex 4 Good Manufacturing Practices for pharmaceutical products: main principles Introduction 37 General considerations 39 Glossary
More informationHarmonizing Change Control Processes Globally
Quality & Compliance Associates, LLC Harmonizing Change Control Processes Globally President Quality & Compliance Associates, LLC When We Deal In A Global Environment, How Do We Design A System That Addresses
More informationHIPAA Privacy Policy & Notice of Privacy Practices
HIPAA Privacy Policy & Notice of Privacy Practices 1. PURPOSE 1 The purpose of this policy is to comply with patient personal health information security rights and privacy regulations as outlined in the
More informationSchweppes Australia Head Office Level 5, 111 Cecil Street South Melbourne Victoria 3205. www.schweppesaustralia.com.au
Schweppes Australia Head Office Level 5, 111 Cecil Street South Melbourne Victoria 3205 www.schweppesaustralia.com.au Quality Management Systems 1. Quality Management Systems develop, implement, verify
More informationIt s all about managing food. Food Recall Plan Template For Food Distributors
It s all about managing food. Food Recall Plan Template For Food Distributors What to Do In The Event Of a Product Recall Every Food Distributor and Food Manufacturer must track the products they manufacture
More informationMonitoring. Compliant and Reasonable. 5-6 May 2015, Berlin, Germany
Environmental Monitoring Workshops How to Establish an Environmental Monitoring Programme Interpretation of OOS Results Compliant and Reasonable 5-6 May 2015, Berlin, Germany SPEAKERS: Oxoid, UK Sauflon
More informationBuilding the Business Case for Automated Rapid Testing: Translating the benefits of rapid automated microbial testing into dollars saved
Building the Business Case for Automated Rapid Testing: Translating the benefits of rapid automated microbial testing into dollars saved A whitepaper by: Opportunities in Micro Quality Control According
More informationREGULATIONS COMPLIANCE ASSESSMENT
ALIX is free software: you can redistribute it and/or modify it under the terms of the GNU General Public License as published by the Free Software Foundation. REGULATIONS COMPLIANCE ASSESSMENT BUSINESS
More informationTHE CAPITAL MARKETS INSURANCE AND SAVINGS DIVISION Annual Report JERUSALEM, DECEMBER 2013
THE CAPITAL MARKETS INSURANCE AND SAVINGS DIVISION Annual Report 2012 JERUSALEM, DECEMBER 2013 Annual Report 2 2012 Ministry Of Finance The Capital Markets Insurance And Savings Division PREFACE Table
More informationPHARMACEUTICAL QUALITY SYSTEM Q10
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE PHARMACEUTICAL QUALITY SYSTEM Q10 Current Step
More informationICH Q7 GMP for Active Pharmaceutical Ingredients
National University of Singapore Academy of GxP Excellence (NUSAGE) and PharmEng Technology Presents ICH Q7 GMP for Active Pharmaceutical Ingredients Part of the Pharmaceutical Biotechnology Training Courses
More informationAPPENDIX 7-B SUGGESTED OUTLINE OF A QUALITY ASSURANCE PROJECT PLAN
APPENDIX 7-B SUGGESTED OUTLINE OF A QUALITY ASSURANCE PROJECT PLAN This outline is recommended for use by UST consultants/contractors in preparing a generic Quality Assurance Project Plan (QAPP) for use
More informationBRAIN PERFORMANCE & PSYCHOLOGY CENTER NOTICE OF PRIVACY PRACTICES
BRAIN PERFORMANCE & PSYCHOLOGY CENTER NOTICE OF PRIVACY PRACTICES Effective Date: 10-20-2014 THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND HOW YOU CAN GET ACCESS
More informationREPRODUCTIVE BIOLOGY ASSOCIATES, LLP HIPAA MANUAL NOTICE OF PRIVACY PRACTICES
NOTICE OF PRIVACY PRACTICES THIS NOTICE DESCRIBES HOW YOUR HEALTH INFORMATION MAY BE USED AND DISCLOSED AND HOW YOU CAN GET ACCESS TO THIS INFORMATION. PLEASE REVIEW IT CAREFULLY. OUR PLEDGE TO YOU: Reproductive
More informationReproductive Medicine Associates of New Jersey, LLC
NOTICE OF PRIVACY PRACTICES Effective Date: September 20, 2013 Last Modified: May 12, 2013 THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND HOW YOU CAN GET ACCESS TO
More informationGLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group dpifat@bcg-usa.com
GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group dpifat@bcg-usa.com Common Misconception Good Laboratory Practices 1) A quality system concerned with the organizational process
More informationChapter 16. Competitive Negotiation: Negotiations
Chapter 16. Competitive Negotiation: Negotiations Summary This chapter establishes the procedure for conducting negotiations with vendors selected by the selection committee following evaluation of the
More informationCOMMISSION DIRECTIVE 2003/94/EC
L 262/22 COMMISSION DIRECTIVE 2003/94/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal
More informationAnnex 9 Guide to good storage practices for pharmaceuticals 1
World Health Organization WHO Technical Report Series, No. 908, 2003 Annex 9 Guide to good storage practices for pharmaceuticals 1 1. Introduction 125 2. Glossary 126 3. Personnel 128 4. Premises and facilities
More informationNational Home Health Care HIPAA Notice of Privacy Practices
Effective Date: THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND HOW YOU CAN GET ACCESS TO THIS INFORMATION. PLEASE REVIEW IT CAREFULLY. If you have any questions about
More informationFOOD SAFETY MANAGEMENT SYSTEMS (FSMS): REQUIREMENTS FOR ANY ORGANISATION IN THE FOOD CHAIN (ISO 22000:2005)
FOOD SAFETY MANAGEMENT SYSTEMS (FSMS): REQUIREMENTS FOR ANY ORGANISATION IN THE FOOD CHAIN (ISO 22000:2005) Dr.R.MANAVALAN, M.Pharm., Ph.D. Professor and Research Director, Department of Pharmaceutics,
More informationResources Based, Manufacturing and Consumer Goods Industries Chemicals Industry
EUROPEAN COMMISSION Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs Resources Based, Manufacturing and Consumer Goods Industries Chemicals Industry Version March 2015 QUESTIONS
More informationGuidance for Industry. Q10 Pharmaceutical Quality System
Guidance for Industry Q10 Pharmaceutical Quality System U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation
More informationShort Course Provider Full Inspection
BRITISH ACCREDITATION COUNCIL INSPECTION REPORT Short Course Provider Full Inspection ORGANISATION: ADDRESS: JD Image Promotions Ltd (UK) 2 Lord Hills Road London W2 6PD HEAD OF ORGANISATION: Mr Rajesh
More informationFDA Title 21 CFR Part 11:Electronic Records; Electronic Signatures; Final Rule (1997)
www.qadata.co.za Introduction FDA Title 21 CFR Part 11:Electronic Records; Electronic Signatures; Final Rule (1997) INITIAL REGULATION RELEASED High profile audit findings Industry complaints to wasting
More informationThe College of William and Mary Division of Sports Medicine. Notice of Privacy Practices
Notice of Privacy Practices This notice describes how medical information about you may be used and disclosed and how you can get access to this information. Please review it carefully. If you have any
More informationMaking SOP Training More Effective
By David Peterson, Director, GMP and Quality Systems, UL EduNeering SOPs are critical to efficient operations, quality control and regulatory compliance. This paper reviews best practices for the Life
More informationAnnex 2. WHO good manufacturing practices for pharmaceutical products: main principles 1
Annex 2 WHO good manufacturing practices for pharmaceutical products: main principles 1 Introduction 79 General considerations 80 Glossary 81 Quality management in the medicines industry: philosophy and
More informationOCCUPATIONAL STANDARD (For use in the development of supply chain related job descriptions, performance evaluations, career development plans, etc.
OCCUPATIONAL STANDARD (For use in the development of supply chain related job descriptions, performance evaluations, career development plans, etc.) Description of Position (As defined by the CSCSC Stakeholder
More informationEconomic profile of the IIHF ice rink prototype
Economic profile of the IIHF ice rink prototype 38 4.1 Introduction There are a lot of construction projects for new buildings of any use running all around the world continuously. The operation of these
More informationEQUASS ASSURANCE AUDITOR TRAINING
EQUASS ASSURANCE AUDITOR TRAINING Date: 13 & 14 January 2010 Location: Clarion Hotel Oslo Airport Hans Gaarderveg 15 2060 Gardermoen, Norway Trainer: Guus van Beek, EQUASS Executive Manager Description:
More informationSupplement to the Guidance for Electronic Data Capture in Clinical Trials
Supplement to the Guidance for Electronic Data Capture in Clinical Trials January 10, 2012 Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association Note: The original language of this
More informationSchindler Elevator Corporation
-4539 Telephone: (973) 397-6500 Mail Address: P.O. Box 1935 Morristown, NJ 07962-1935 NOTICE OF PRIVACY PRACTICES FOR PROTECTED HEALTH INFORMATION THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU
More informationQuality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle
Quality Risk Management 11 November 2011 Galway, Ireland Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle Overview Regulatory
More informationRisk Based Pre-Approval Inspection
Risk Based Pre-Approval Inspection PQRI-FDA Conference on Advancing Product Quality October 5, 2015 Christine Moore, Ph.D. Acting Director, Office of Process and Facilities FDA/CDER/OPQ Outline Background
More informationGCP INSPECTORS WORKING GROUP <DRAFT> REFLECTION PAPER ON EXPECTATIONS FOR ELECTRONIC SOURCE DOCUMENTS USED IN CLINICAL TRIALS
European Medicines Agency London, 17 October 2007 Doc. Ref. EMEA/505620/2007 GCP INSPECTORS WORKING GROUP REFLECTION PAPER ON EXPECTATIONS FOR ELECTRONIC SOURCE DOCUMENTS USED IN CLINICAL TRIALS
More informationThe FDA recently announced a significant
This article illustrates the risk analysis guidance discussed in GAMP 4. 5 By applying GAMP s risk analysis method to three generic classes of software systems, this article acts as both an introduction
More informationWork plan for GMP/GDP Inspectors Working Group for 2016
21 December 2015 EMA/INS/GMP/738756/2015 Compliance and Inspection Work plan for GMP/GDP Inspectors Working Group for 2016 Chairperson: Status David Cockburn January 2016 1. Meetings scheduled for 2016
More informationKiran Mishra, Ph.D. Licensed Clinical Psychologist. Sugar Land, TX 77478 (832) 876-3232 TEXAS NOTICE FORM
Kiran Mishra, Ph.D. Licensed Clinical Psychologist 1111 Highway 6, Suite 235 Sugar Land, TX 77478 (832) 876-3232 TEXAS NOTICE FORM Notice of Psychologists Policies and Practices to Protect the Privacy
More informationNOTICE OF PRIVACY PRACTICES
Page 1 of 6 NOTICE OF PRIVACY PRACTICES Revised: June 15, 2014 THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND HOW YOU CAN GET ACCESS TO THIS INFORMATION. PLEASE REVIEW
More information